The Effect of Vitamin D Supplementation on Recurrence-Free Survival in Melanoma Patients: A Systematic Review and Meta-Analysis
Keywords:
Vitamin D Supplementation, Melanoma patients, Recurrence-free survival, Meta-analysisAbstract
Introduction: Vitamin D has been proposed as a potential adjunctive therapy in melanoma based on its biological effects on tumor cells and immune modulation. However, the clinical benefit of vitamin D supplementation in reducing melanoma recurrence or progression remains uncertain.
Objective: To systematically evaluate the impact of vitamin D supplementation on recurrence-free survival in patients with melanoma.
Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. Eligible studies included randomized controlled trials and cohort studies comparing vitamin D supplementation to placebo or no supplementation in melanoma patients and reporting recurrence-free, disease-free, or progression-free survival. Data were synthesized using a random-effects model, and hazard ratios (HRs) were pooled.
Results: Three studies (n=739) were included, encompassing both adjuvant and advanced melanoma settings. The pooled analysis demonstrated no statistically significant association between vitamin D supplementation and improved recurrence-free survival (HR 0.83, 95% CI: 0.52–1.32; p = 0.43). Moderate heterogeneity was observed. Only one study, involving patients treated with anti–PD-1 immunotherapy, showed a significant benefit, whereas randomized trials in the adjuvant setting did not.
Discussion: Although preclinical and observational data support a potential role for vitamin D in melanoma, clinical trial evidence does not demonstrate a significant effect on recurrence-free survival. Heterogeneity in study populations, supplementation regimens, and timing may influence outcomes.
Conclusion: Vitamin D supplementation cannot currently be recommended solely to prevent recurrence or progression in melanoma, but remains important for general health. Further research, particularly in the context of immunotherapy, is warranted.
References
Whiteman DC, Green AC, Olsen CM. The Growing Burden of Invasive Melanoma: Projections of Incidence Rates and Numbers of New Cases in Six Susceptible Populations through 2031. Journal of Investigative Dermatology. 2016 Jun;136(6):1161–71.
Wang M, Gao X, Zhang L. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chin Med J (Engl). 2025 Jan 20;138(2):185–92.
Robert C, Schachter J, Long G V., Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2015 Jun 25;372(26):2521–32.
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long G V., Ross MI, et al. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov 13;67(6):472–92.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine. 2019 Oct 17;381(16):1535–46.
Friedman CF, Spencer C, Cabanski CR, Panageas KS, Wells DK, Ribas A, et al. Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. J Immunother Cancer. 2022 Jan 24;10(1):e003853.
Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al. Meta‐analysis of observational studies of serum 25‐hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011 Mar 15;128(6):1414–24.
Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Laboratory Investigation. 2017 Jun;97(6):706–24.
Wyatt C, Neale RE, Lucas RM. Skin Cancer and Vitamin D: An Update. Melanoma Manag. 2015 Feb 25;2(1):51–61.
Saiag P, Aegerter P, Vitoux D, Lebbé C, Wolkenstein P, Dupin N, et al. Prognostic Value of 25-hydroxyvitamin D3 Levels at Diagnosis and During Follow-up in Melanoma Patients. J Natl Cancer Inst. 2015 Dec 15;107(12):djv264.
HADDAD S, WEISE JJ, WAGENPFEIL S, VOGT T, REICHRATH J. Malignant Melanoma: Vitamin D Status as a Risk and Prognostic Factor – Meta-analyses and Systematic Review. Anticancer Res. 2025 Jan 30;45(1):27–37.
Slominski AT, Zmijewski MA, Skobowiat C, Zbytek B, Slominski RM, Steketee JD. Introduction. In 2012. p. 1–6.
Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-Hydroxyvitamin D 3 Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma. Journal of Clinical Oncology. 2009 Nov 10;27(32):5439–44.
De Smedt J, Van Kelst S, Janssen L, Marasigan V, Boecxstaens V, Bogaerts K, et al. High-dose vitamin D supplementation does not improve outcome in a cutaneous melanoma population: results of a randomized double-blind placebo-controlled study (ViDMe trial). British Journal of Dermatology. 2024 Nov 18;191(6):886–96.
Gwenzi T, Zhu A, Schrotz-King P, Schöttker B, Hoffmeister M, Brenner H. Effects of vitamin D supplementation on inflammatory response in patients with cancer and precancerous lesions: Systematic review and meta-analysis of randomized trials. Clinical Nutrition. 2023 Jul;42(7):1142–50.
Slominski AT, Brożyna AA, Zmijewski MA, Jóźwicki W, Jetten AM, Mason RS, et al. Vitamin D signaling and melanoma: role of vitamin D and its receptors in melanoma progression and management. Laboratory Investigation. 2017 Jun;97(6):706–24.
Gnagnarella P, Raimondi S, Aristarco V, Johansson HA, Bellerba F, Corso F, et al. Vitamin D Receptor Polymorphisms and Cancer. In 2020. p. 53–114.
Cust AE, Jenkins MA, Goumas C, Armstrong BK, Schmid H, Aitken JF, et al. Early-life sun exposure and risk of melanoma before age 40 years. Cancer Causes & Control. 2011 Jun 7;22(6):885–97.
Moro R, Sánchez-Silva A, Aguerralde-Martin M, González-Cuevas R, Peruilh-Bagolini L, Traves V, et al. Efecto de los niveles séricos de vitamina D en el pronóstico del melanoma cutáneo. Actas Dermosifiliogr. 2022 Apr;113(4):347–53.
Chandler PD, Chen WY, Ajala ON, Hazra A, Cook N, Bubes V, et al. Effect of Vitamin D 3 Supplements on Development of Advanced Cancer. JAMA Netw Open. 2020 Nov 18;3(11):e2025850.
Vrieling A, Seibold P, Johnson TS, Heinz J, Obi N, Kaaks R, et al. Circulating 25‐hydroxyvitamin D and postmenopausal breast cancer survival: Influence of tumor characteristics and lifestyle factors? Int J Cancer. 2014 Jun 15;134(12):2972–83.
Zgaga L, Theodoratou E, Farrington SM, Din FVN, Ooi LY, Glodzik D, et al. Plasma Vitamin D Concentration Influences Survival Outcome After a Diagnosis of Colorectal Cancer. Journal of Clinical Oncology. 2014 Aug 10;32(23):2430–9.
Hernández-Alonso P, Boughanem H, Canudas S, Becerra-Tomás N, Fernández de la Puente M, Babio N, et al. Circulating vitamin D levels and colorectal cancer risk: A meta-analysis and systematic review of case-control and prospective cohort studies. Crit Rev Food Sci Nutr. 2023 Jan 2;63(1):1–17.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Aldila Ardine, Raisa Khairuni (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors publishing here keep copyright but grant the journal first publication rights, under a Creative Commons Attribution-NonCommercial 4.0 License. They can distribute their work non-exclusively elsewhere with an acknowledgment of its first publication in this journal. Posting the work online before and during submission for earlier and greater citation is encouraged, reflecting Open Access benefits.
